CervoMed Shows Progress in Treating Rare Aphasia ConditionBenzinga · Oct 12, 2026
CervoMed (NASDAQ:CRVO) Earns “Buy” Rating from HC WainwrightDefense World · Oct 5, 2026
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of “Moderate Buy” from BrokeragesDefense World · Oct 3, 2026
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure LimitGlobeNewsWire · Sep 28, 2026
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities ConferenceGlobeNewsWire · Sep 22, 2026
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026GlobeNewsWire · Sep 10, 2026CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.87 | -$0.64 | Beat |
| May 18, 2026 | -$0.90 | -$0.86 | Beat |
| Mar 13, 2026 | -$0.79 | -$0.88 | Miss |
| Nov 7, 2025 | -$0.68 | -$0.84 | Miss |
| Aug 8, 2025 | -$0.61 | -$0.70 | Miss |
| May 12, 2025 | -$0.60 | -$0.56 | Beat |